Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

1.

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.

Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, Tan AL, Sin Poh DY, Riahi S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yong WP, Cheong HC, Rha SY, Boussioutas A, Grabsch H, Rozen S, Tan P.

Gut. 2012 May;61(5):673-84. doi: 10.1136/gutjnl-2011-301839. Epub 2012 Feb 7.

PMID:
22315472
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.

Liu YJ, Shen D, Yin X, Gavine P, Zhang T, Su X, Zhan P, Xu Y, Lv J, Qian J, Liu C, Sun Y, Qian Z, Zhang J, Gu Y, Ni X.

Br J Cancer. 2014 Mar 4;110(5):1169-78. doi: 10.1038/bjc.2014.61. Epub 2014 Feb 11.

PMID:
24518603
[PubMed - indexed for MEDLINE]
3.

Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.

Matsubara D, Ishikawa S, Sachiko O, Aburatani H, Fukayama M, Niki T.

Am J Pathol. 2010 Nov;177(5):2191-204. doi: 10.2353/ajpath.2010.100217. Epub 2010 Oct 7.

PMID:
20934974
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.

Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, Gao B, Shen D, Zhang L, Ji J, Gavine PR, Zhang J, Kilgour E, Zhang X, Ji Q.

Clin Cancer Res. 2013 May 1;19(9):2572-83. doi: 10.1158/1078-0432.CCR-12-3898. Epub 2013 Mar 14.

PMID:
23493349
[PubMed - indexed for MEDLINE]
Free Article
5.

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.

Staaf J, Jönsson G, Ringnér M, Vallon-Christersson J, Grabau D, Arason A, Gunnarsson H, Agnarsson BA, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A.

Breast Cancer Res. 2010;12(3):R25. doi: 10.1186/bcr2568. Epub 2010 May 6.

PMID:
20459607
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma.

Kato H, Arao T, Matsumoto K, Fujita Y, Kimura H, Hayashi H, Nishiki K, Iwama M, Shiraishi O, Yasuda A, Shinkai M, Imano M, Imamoto H, Yasuda T, Okuno K, Shiozaki H, Nishio K.

Int J Oncol. 2013 Apr;42(4):1151-8. doi: 10.3892/ijo.2013.1830. Epub 2013 Feb 19.

PMID:
23426935
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.

Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, Yashiro M, Hirakawa K, Hirai M, Minami H.

Invest New Drugs. 2012 Aug;30(4):1352-60. doi: 10.1007/s10637-011-9699-0. Epub 2011 Jun 8.

PMID:
21655918
[PubMed - indexed for MEDLINE]
8.

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.

Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS.

Gastroenterology. 2012 Apr;142(4):1021-1031.e15. doi: 10.1053/j.gastro.2011.12.005. Epub 2011 Dec 13.

PMID:
22178589
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors.

Yamaguchi H, Takanashi M, Yoshida N, Ito Y, Kamata R, Fukami K, Yanagihara K, Sakai R.

Cancer Sci. 2014 May;105(5):528-36. doi: 10.1111/cas.12387. Epub 2014 Mar 24.

PMID:
24612061
[PubMed - indexed for MEDLINE]
10.

Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.

Matsubara D, Ishikawa S, Oguni S, Aburatani H, Fukayama M, Niki T.

J Thorac Oncol. 2010 Sep;5(9):1317-24. doi: 10.1097/JTO.0b013e3181e2a409.

PMID:
20736805
[PubMed - indexed for MEDLINE]
11.

Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer.

Tsujimoto H, Sugihara H, Hagiwara A, Hattori T.

Virchows Arch. 1997 Dec;431(6):383-9.

PMID:
9428926
[PubMed - indexed for MEDLINE]
12.

Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion.

Asaoka Y, Tada M, Ikenoue T, Seto M, Imai M, Miyabayashi K, Yamamoto K, Yamamoto S, Kudo Y, Mohri D, Isomura Y, Ijichi H, Tateishi K, Kanai F, Ogawa S, Omata M, Koike K.

Biochem Biophys Res Commun. 2010 Apr 16;394(4):1042-6. doi: 10.1016/j.bbrc.2010.03.120. Epub 2010 Mar 21.

PMID:
20331976
[PubMed - indexed for MEDLINE]
13.

The impact of genomic changes on treatment of lung cancer.

Cardarella S, Johnson BE.

Am J Respir Crit Care Med. 2013 Oct 1;188(7):770-5. doi: 10.1164/rccm.201305-0843PP. Review.

PMID:
23841470
[PubMed - indexed for MEDLINE]
14.

Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy.

Lee S, Kim Y, Sun JM, Choi YL, Kim JG, Shim YM, Park YH, Ahn JS, Park K, Han JH, Ahn MJ.

J Cancer Res Clin Oncol. 2011 Aug;137(8):1203-11. doi: 10.1007/s00432-011-0986-0. Epub 2011 May 28.

PMID:
21626008
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.

Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR.

Mol Cancer Ther. 2012 Mar;11(3):660-9. doi: 10.1158/1535-7163.MCT-11-0754. Epub 2012 Jan 11.

PMID:
22238368
[PubMed - indexed for MEDLINE]
Free Article
16.

Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.

André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J.

Clin Cancer Res. 2013 Jul 1;19(13):3693-702. doi: 10.1158/1078-0432.CCR-13-0190. Epub 2013 May 8.

PMID:
23658459
[PubMed - indexed for MEDLINE]
Free Article
17.

Epidermal growth factor receptor structural alterations in gastric cancer.

Moutinho C, Mateus AR, Milanezi F, Carneiro F, Seruca R, Suriano G.

BMC Cancer. 2008 Jan 16;8:10. doi: 10.1186/1471-2407-8-10.

PMID:
18199332
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer.

Staaf J, Jönsson G, Ringnér M, Baldetorp B, Borg A.

Breast Cancer Res. 2011;13(6):R129. doi: 10.1186/bcr3075. Epub 2011 Dec 14.

PMID:
22169037
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.

Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T.

J Thorac Oncol. 2009 Jan;4(1):5-11. doi: 10.1097/JTO.0b013e3181913e0e.

PMID:
19096300
[PubMed - indexed for MEDLINE]
20.

Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization.

Tajiri R, Ooi A, Fujimura T, Dobashi Y, Oyama T, Nakamura R, Ikeda H.

Hum Pathol. 2014 Apr;45(4):725-34. doi: 10.1016/j.humpath.2013.11.004. Epub 2013 Nov 15.

PMID:
24491355
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk